« Value Focused Commercial Model = Opportunity Knocking | Main | Focus on Discovery, Not Decision-Making, Is Key To Success »

09/22/2010

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a0120a77f675b970b0133f4747f4f970b

Listed below are links to weblogs that reference The Novartis MS Pill: Bitter for BiogenIdec? :

Comments

Feed You can follow this conversation by subscribing to the comment feed for this post.

bigredbruce

More from in-Pharma Technologist on prospects for entire MS market which is expected to growth robustly through 2015.
http://www.in-pharmatechnologist.com/Industry-Drivers/Soaring-growth-anticipated-in-MS-therapies-market-says-report?utm_source=RSS_text_news

bigredbruce

Round up of MS drug activity for week (Sept 26th) as recounted in Seeking Alpha
http://seekingalpha.com/article/227056-a-busy-week-for-multiple-sclerosis-news

bigredbruce

More from the Forbes blog on Novartis-Biogen dynamics with MS drugs
http://blogs.forbes.com/matthewherper/2010/09/22/why-novartis-approval-is-bad-for-biogen/

The comments to this entry are closed.

My Photo
Blog powered by Typepad
Member since 12/2009
Bookmark and Share

July 2014

Sun Mon Tue Wed Thu Fri Sat
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

Innovate on Purpose

In the Pipeline

Life Sci VC


visited 6 states (46.1%)
Create your own visited map of Canada